Literature DB >> 21688077

The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles.

Naosuke Nonoguchi1, Shin-Ichi Miyatake, Motoi Fukumoto, Motomasa Furuse, Ryo Hiramatsu, Shinji Kawabata, Toshihiko Kuroiwa, Motomu Tsuji, Manabu Fukumoto, Koji Ono.   

Abstract

The cell type and localization of vascular endothelial growth factor (VEGF)-producing cells in human radiation necrosis (RN) are investigated from a histopathological and immunohistochemical standpoint using clinical specimens. Eighteen surgical specimens of symptomatic RN in the brain were retrospectively reviewed. These cases included different original histological tumor types and were treated with different radiation modalities. Histological analyses were performed using hematoxylin and eosin (H&E) staining, and anti-VEGF and anti-hypoxia-inducible factor (HIF)-1α immunohistochemistry. H&E staining showed marked angiogenesis and reactive astrocytosis at the perinecrotic area. The most prominent vasculature in this area was identified as telangiectasis. Immunohistochemistry indicated that HIF-1α was expressed predominantly in the perinecrotic area and that a large majority of VEGF-expressing cells were reactive astrocytes intensively distributed in this area. VEGF produced by the reactive astrocytes localized mainly in the perinecrotic area might be a major cause of both angiogenesis and the subsequent perilesional edema typically found in RN of the brain. The benefits of anti-VEGF antibody (bevacizumab) treatment in RN may be that VEGF secretion from the perinecrotic tissue is inhibited and that surgery would remove this tissue; both of these benefits result in effective reduction of edema associated with RN.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21688077     DOI: 10.1007/s11060-011-0610-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

1.  Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence.

Authors:  W Stummer; S Stocker; S Wagner; H Stepp; C Fritsch; C Goetz; A E Goetz; R Kiefmann; H J Reulen
Journal:  Neurosurgery       Date:  1998-03       Impact factor: 4.654

2.  Hypoxia in radiation-induced blood-spinal cord barrier breakdown.

Authors:  Y Q Li; J R Ballinger; R A Nordal; Z F Su; C S Wong
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

3.  Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages.

Authors:  Shin-Ichi Miyatake; Shinji Kawabata; Yoshinaga Kajimoto; Atsushi Aoki; Kunio Yokoyama; Makoto Yamada; Toshihiko Kuroiwa; Motomu Tsuji; Yoshio Imahori; Mitsunori Kirihata; Yoshinori Sakurai; Shin-Ichiro Masunaga; Kenji Nagata; Akira Maruhashi; Koji Ono
Journal:  J Neurosurg       Date:  2005-12       Impact factor: 5.115

4.  Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases.

Authors:  Motomasa Furuse; Shinji Kawabata; Toshihiko Kuroiwa; Shin-Ichi Miyatake
Journal:  J Neurooncol       Date:  2010-08-07       Impact factor: 4.130

5.  Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells.

Authors:  E Ikeda; M G Achen; G Breier; W Risau
Journal:  J Biol Chem       Date:  1995-08-25       Impact factor: 5.157

6.  Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas.

Authors:  Minoru Miyashita; Shin-Ichi Miyatake; Yoshio Imahori; Kunio Yokoyama; Shinji Kawabata; Yoshinaga Kajimoto; Masa-Aki Shibata; Yoshinori Otsuki; Mitsunori Kirihata; Koji Ono; Toshihiko Kuroiwa
Journal:  J Neurooncol       Date:  2008-06-20       Impact factor: 4.130

7.  Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo.

Authors:  A Minchenko; T Bauer; S Salceda; J Caro
Journal:  Lab Invest       Date:  1994-09       Impact factor: 5.662

Review 8.  The morphologic effects of radiation administered therapeutically for intracranial gliomas: a postmortem study of 25 cases.

Authors:  P C Burger; M S Mahley; L Dudka; F S Vogel
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

9.  In vivo imaging shows abnormal function of vascular endothelial growth factor-induced vasculature.

Authors:  Serena Zacchigna; Ennio Tasciotti; Claudia Kusmic; Nikola Arsic; Oreste Sorace; Cecilia Marini; Paolo Marzullo; Silvia Pardini; Debora Petroni; Lucia Pattarini; Silvia Moimas; Mauro Giacca; Gianmario Sambuceti
Journal:  Hum Gene Ther       Date:  2007-06       Impact factor: 5.695

10.  Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor.

Authors:  Robert A Nordal; Andras Nagy; Melania Pintilie; C Shun Wong
Journal:  Clin Cancer Res       Date:  2004-05-15       Impact factor: 12.531

View more
  48 in total

1.  Laser interstitial thermal therapy (LITT) vs. bevacizumab for radiation necrosis in previously irradiated brain metastases.

Authors:  Nanthiya Sujijantarat; Christopher S Hong; Kent A Owusu; Aladine A Elsamadicy; Joseph P Antonios; Andrew B Koo; Joachim M Baehring; Veronica L Chiang
Journal:  J Neurooncol       Date:  2020-06-29       Impact factor: 4.130

2.  Efficacy of repeated low-dose bevacizumab treatment with long-dosing interval for radiation-induced brain necrosis: A case report.

Authors:  Xiangying Meng; Rugang Zhao; Shikai Wu; Ge Shen; Lijuan Ding; Bing Sun; Junliang Wang
Journal:  Cancer Biol Ther       Date:  2017-01-02       Impact factor: 4.742

3.  An analysis of radiation necrosis of the central nervous system treated with bevacizumab.

Authors:  Karen Tye; Herbert H Engelhard; Konstantin V Slavin; M Kelly Nicholas; Steven J Chmura; Young Kwok; Dominic S Ho; Ralph R Weichselbaum; Matthew Koshy
Journal:  J Neurooncol       Date:  2014-02-07       Impact factor: 4.130

Review 4.  Delayed brain radiation necrosis: pathological review and new molecular targets for treatment.

Authors:  Motomasa Furuse; Naosuke Nonoguchi; Shinji Kawabata; Shin-Ichi Miyatake; Toshihiko Kuroiwa
Journal:  Med Mol Morphol       Date:  2015-12       Impact factor: 2.309

5.  Distinct Expression of Various Angiogenesis Factors in Mice Brain After Whole-Brain Irradiation by X-ray.

Authors:  Zhezhi Deng; Haiwei Huang; Xiaohong Wu; Mengmeng Wu; Guoyong He; Junjie Guo
Journal:  Neurochem Res       Date:  2016-11-25       Impact factor: 3.996

6.  Specificity of vascular endothelial growth factor treatment for radiation necrosis.

Authors:  Carlos J Perez-Torres; Liya Yuan; Robert E Schmidt; Keith M Rich; Robert E Drzymala; Dennis E Hallahan; Joseph J H Ackerman; Joel R Garbow
Journal:  Radiother Oncol       Date:  2015-09-12       Impact factor: 6.280

Review 7.  Antiangiogenic therapy for glioblastoma.

Authors:  Elizabeth R Gerstner; Tracy T Batchelor
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

8.  The Effectiveness of Bevacizumab in Radionecrosis After Radiosurgery of a Single Brain Metastasis.

Authors:  Durim Delishaj; Stefano Ursino; Francesco Pasqualetti; Ilaria Pesaresi; Ilaria Desideri; Mirco Cosottini; Concetta Laliscia; Fabiola Paiar; Maria Grazia Fabrini
Journal:  Rare Tumors       Date:  2015-12-29

9.  Salvage stereotactic radiosurgery with adjuvant use of bevacizumab for heavily treated recurrent brain metastases: a preliminary report.

Authors:  Shoji Yomo; Motohiro Hayashi
Journal:  J Neurooncol       Date:  2015-11-30       Impact factor: 4.130

10.  Pseudo-progression after stereotactic radiotherapy of brain metastases: lesion analysis using MRI cine-loops.

Authors:  Ruud Wiggenraad; Petra Bos; Antoinette Verbeek-de Kanter; Geert Lycklama À Nijeholt; Jan van Santvoort; Martin Taphoorn; Henk Struikmans
Journal:  J Neurooncol       Date:  2014-07-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.